» Articles » PMID: 38994941

Tumor Dormancy and Reactivation: The Role of Heat Shock Proteins

Overview
Journal Cells
Publisher MDPI
Date 2024 Jul 12
PMID 38994941
Authors
Affiliations
Soon will be listed here.
Abstract

Tumors are a heterogeneous group of cell masses originating in various organs or tissues. The cellular composition of the tumor cell mass interacts in an intricate manner, influenced by humoral, genetic, molecular, and tumor microenvironment cues that dictate tumor growth or suppression. As a result, tumors undergo a period of a dormant state before their clinically discernible stage, which surpasses the clinical dormancy threshold. Moreover, as a genetically imprinted strategy, early-seeder cells, a distinct population of tumor cells, break off to dock nearby or extravasate into blood vessels to secondary tissues, where they form disseminated solitary dormant tumor cells with reversible capacity. Among the various mechanisms underlying the dormant tumor mass and dormant tumor cell formation, heat shock proteins (HSPs) might play one of the most important roles in how the dormancy program plays out. It is known that numerous aberrant cellular processes, such as malignant transformation, cancer cell stemness, tumor invasion, metastasis, angiogenesis, and signaling pathway maintenance, are influenced by the HSPs. An accumulating body of knowledge suggests that HSPs may be involved in the angiogenic switch, immune editing, and extracellular matrix (ECM) remodeling cascades, crucial genetically imprinted strategies important to the tumor dormancy initiation and dormancy maintenance program. In this review, we highlight the biological events that orchestrate the dormancy state and the body of work that has been conducted on the dynamics of HSPs in a tumor mass, as well as tumor cell dormancy and reactivation. Additionally, we propose a conceptual framework that could possibly underlie dormant tumor reactivation in metastatic relapse.

Citing Articles

Deciphering the Role of Cancer Stem Cells: Drivers of Tumor Evolution, Therapeutic Resistance, and Precision Medicine Strategies.

El-Tanani M, Rabbani S, Satyam S, Rangraze I, Wali A, El-Tanani Y Cancers (Basel). 2025; 17(3).

PMID: 39941751 PMC: 11815874. DOI: 10.3390/cancers17030382.

References
1.
Tian Y, Wang C, Chen S, Liu J, Fu Y, Luo Y . Extracellular Hsp90α and clusterin synergistically promote breast cancer epithelial-to-mesenchymal transition and metastasis via LRP1. J Cell Sci. 2019; 132(15). DOI: 10.1242/jcs.228213. View

2.
Kobayashi A, Okuda H, Xing F, Pandey P, Watabe M, Hirota S . Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med. 2011; 208(13):2641-55. PMC: 3244043. DOI: 10.1084/jem.20110840. View

3.
DeZwaan D, Freeman B . HSP90 manages the ends. Trends Biochem Sci. 2010; 35(7):384-91. PMC: 2891936. DOI: 10.1016/j.tibs.2010.02.005. View

4.
Albrengues J, Shields M, Ng D, Park C, Ambrico A, Poindexter M . Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science. 2018; 361(6409). PMC: 6777850. DOI: 10.1126/science.aao4227. View

5.
Chen F, Chandrashekar D, Scheurer M, Varambally S, Creighton C . Global molecular alterations involving recurrence or progression of pediatric brain tumors. Neoplasia. 2021; 24(1):22-33. PMC: 8649620. DOI: 10.1016/j.neo.2021.11.014. View